GSK Lung Drug Fails to Meet Primary Goal in Clinical Trial Print E-mail
By Staff and Wire Reports   
Wednesday, 16 September 2015 12:39

GlaxoSmithKline’s Breo Ellipta failed to meet its primary goal in a pivotal clinical trial of curbing death risk in patients suffering from chronic pulmonary obstructive disease.

The British pharmaceutical giant said last week that the risk of death was 12.2 percent lower among patients receiving the treatment versus placebo, but the results were not statistically significant to prove its ability in extending life.

The study began in 2011 and tracked 16,485 people from 43 countries who had chronic obstructive pulmonary disease, and either a comorbidity or risk of cardiovascular disease. Cardiovascular disease has been shown to double mortality in COPD patients.

 

READ MORE ABOUT GSK'S BREO ELLIPTA HERE




"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!
 

Newsletter